Safety Study of Camptothecin-20-O-Propionate Hydrate (CZ48)

Inclusion Criteria: * Patients must have a Performance Status (Zubrod) performance status of 0-1 * Patients must sign an informed consent document * Patients should have adequate bone marrow function defined by an absolute peripheral granulocyte count of \> 1,500 /mm3 and platelet count \>100,000/mm3 along with an absence of a red blood cell transfusion in the two weeks prior to their participation in the trial * Patients should have adequate hepatic function with a total bilirubin within normal range and serum glutamate oxaloacetate transaminase (SGOT) or serum glutamate pyruvate transaminase (SGPT) \< two times the upper limit of normal (ULN) for patients without liver metastasis and SGOT or SGPT \< five times ULN for those with liver metastasis, and adequate renal function as defined by a serum creatinine within 1.5 times the upper limit of normal. * Patients may receive no other concurrent anticancer treatments such as chemotherapy, hormone therapy (except for prostate cancer patients on luteinizing hormone-releasing hormone ((LHRH)) agonists), immunotherapy, biological agents, investigational agents, or radiation therapy during this trial, and should be off these treatments for at least 2 weeks, or until they have completely recovered from the side effects of these treatments, whichever is longest, except for persistent grade 1 neuropathy in patients who received prior platinum or taxanes. Exclusion Criteria: * Patients with symptomatic brain metastases are excluded from this study. * Patients with brain metastasis that have been treated, asymptomatic and off any steroid use are permitted for study * Pregnant women or nursing mothers are not eligible for this trial. Patients of child bearing potential must use adequate contraception (contraceptive pill, or intrauterine device ((IUD)), or two mechanical barriers). * Patients with severe uncontrolled medical problems are not eligible for this trial. * Patients who have too much esterase as determined by a pre-screen dose, with a conversion rate yielding concentration of CPT \> 100 ng/ml in vitro.